Study Number:	MOG10866
Study Gender:	Both
PWG Approval Date:	See web page for date of PWG Approval
Version:	v1.1.7

Study Number: MOG10866
Test Type: MOG - Range Finding
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Isopropylated Phenyl Phosphate
CAS Number: 68937-41-7

Date Report Requested: 02/19/2021
Time Report Requested: 13:48:18
Lab: Battelle

F0 Female

		Treatment Groups (ppm)			
	Phase Day	**0**	**1000**	**3000**	**10000**
Blood Acetylcholinesterase (U/mL)	LD 28	0.43 ± 0.01 (10) **	0.08 ± 0.00 (10) **	0.04 ± 0.00 (9) **	0.03 ± 0.01 (10) **
Percent of Control			18.8	9.6	7.7
Blood Butylcholinesterase (U/mL)	LD 28	0.16 ± 0.01 (10) **	0.05 ± 0.00 (10) **	0.02 ± 0.00 (9) **	0.02 ± 0.00 (10) **
Percent of Control			29.6	12.6	10.7

Study Number: MOG10866
Test Type: MOG - Range Finding
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Isopropylated Phenyl Phosphate
CAS Number: 68937-41-7

Date Report Requested: 02/19/2021
Time Report Requested: 13:48:18
Lab: Battelle

F1 Male

		Treatment Groups (ppm)			
	Phase Day	**0**	**1000**	**3000**	**10000**
Blood Acetylcholinesterase (U/mL)	PND 28	0.24 ± 0.01 (10) **	0.11 ± 0.01 (10) **	0.08 ± 0.00 (7) **	0.03 ± 0.00 (10) **
Percent of Control			46.9	30.9	13.9
Brain Acetylcholinesterase (U/g)	PND 28	2.13 ± 0.15 (10) **	1.52 ± 0.11 (10) **	1.27 ± 0.07 (8) **	
Percent of Control			71.6	59.8	
Blood Butylcholinesterase (U/mL)	PND 28	0.07 ± 0.00 (10) **	0.04 ± 0.00 (10) **	0.03 ± 0.00 (7) **	0.02 ± 0.00 (10) **
Percent of Control			59.4	39.3	26.1
Brain ButylCholinesterase (U/g)	PND 28	1.45 ± 0.11 (10) *	1.29 ± 0.10 (10)	1.11 ± 0.05 (8) *	
Percent of Control			88.7	76.7	

Study Number: MOG10866
Test Type: MOG - Range Finding
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Isopropylated Phenyl Phosphate
CAS Number: 68937-41-7

Date Report Requested: 02/19/2021
Time Report Requested: 13:48:18
Lab: Battelle

F1 Female

		Treatment Groups (ppm)			
	Phase Day	**0**	**1000**	**3000**	**10000**
Blood Acetylcholinesterase (U/mL)	PND 28	0.25 ± 0.01 (10) **	0.12 ± 0.00 (9) **	0.08 ± 0.00 (8) **	0.04 ± 0.01 (11) **
Percent of Control			49.9	30.6	18.2
Brain Acetylcholinesterase (U/g)	PND 28	1.99 ± 0.14 (10) **	1.26 ± 0.08 (10) **	1.17 ± 0.06 (8) **	
Percent of Control			63.4	58.9	
Blood Butylcholinesterase (U/mL)	PND 28	0.07 ± 0.00 (10) **	0.04 ± 0.00 (9) **	0.03 ± 0.00 (8) **	0.02 ± 0.00 (11) **
Percent of Control			61.7	39.9	25.3
Brain ButylCholinesterase (U/g)	PND 28	1.31 ± 0.08 (10)	0.95 ± 0.05 (10) **	1.07 ± 0.05 (8)	
Percent of Control			72.9	82.2	

LEGEND

Values given as mean ± SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100

LD – Lactation Day; PND – Postnatal Day, adults post-weaning

Statistical analysis were performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at P <= 0.05

** Statistically significant at P <= 0.01

Brain tissue samples from pups (F1 generation) in the 10,000 ppm dose group were not assessed for ChE activity.

The 30,000 ppm group was terminated on GD12, and the 15,000 ppm group was terminated by LD3/PND3 due to excessive toxicity. Measurements taken from these dose groups were excluded from the analysis.

All F1 animals contained one male or female per litter with the exception of 2 males in the F1-3 dose group (3000 ppm), and animals in the F1-4 dose group (10000 ppm), where litter-mates ranged from 1-7. Litter-based analysis methods were therefore not applicable in the analyses of these data.

** END OF REPORT **